TC BioPharm (Holdings) plc
TCBWF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TCBWF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TCBWF
TC BioPharm is a clinical-stage biotechnology company developing GD-T cell therapies, with lead candidate OmnImmune® in Phase 3 trials for oncology indications.
Key risk: Going Concern and Cash Runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2024.
Tracking 5 clinical trials · 2 catalysts for TC BioPharm (Holdings) plc.
TC BioPharm is a clinical-stage biotechnology company developing GD-T cell therapies, with lead candidate OmnImmune® in Phase 3 trials for oncology indications.
- Cash and cash equivalents of £1.2M as of December 31, 2024 [sec]
- Net loss of £12.2M for fiscal year 2024 [sec]
- Accumulated deficit of £51.0M as of December 31, 2024 [sec]
- Lead product candidate is OmnImmune®, a GD-T cell therapy in Phase 3 development [sec]
- Company expects existing cash to fund operations only to June 2025, raising substantial doubt about going concern [sec]
What works
- Proprietary GD-T cell platform with potential for allogeneic, off-the-shelf therapy, as the company is developing genetically engineered GD-T cell candidates [sec]
- Clinical-stage pipeline: OmnImmune® in Phase 3 trials and preclinical CAR-T programs [sec]
- Company has raised capital through multiple mechanisms including IPO, private placements, and warrant exercises, indicating some access to capital markets [sec]
What to weigh
- Cash runway limited to June 2025, with no committed financing in place for additional capital [sec]
- Accumulated deficit of £51.0M and no near-term revenue expected from product sales [sec]
- Heavy dependence on single lead candidate OmnImmune®; failure would significantly harm the business [sec]
- Clinical development risks: uncertain trial outcomes and regulatory approval not guaranteed [sec]
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2024
“As of December 31, 2024, and December 31, 2023, we had cash and cash equivalents of £1.2 million and £2.5 million, respectively.”
SEC filings · May 9, 2025
Going concern warning – cash only funds operations to June 2025
“Management believes that its existing cash balances will only be able to fund current operations to June 2025.”
SEC filings · May 9, 2025
Dependence on lead product candidate OmnImmune®
“We are heavily dependent on the success of our lead product candidate, OmnImmune®, and our subsequent product development program”
SEC filings · May 9, 2025
Net loss for fiscal year 2024
“For the fiscal years ended December 31, 2024 and 2023, we incurred net losses of £12.2 million and £5.9 million, respectively.”
SEC filings · May 9, 2025
Catalyst timeline
- 2027-06-30 · Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the — Topline data from this placebo-controlled Phase 3 trial of OmnImmune®.
- 2028-10-24 · Phase 3 Topline: A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Clinical Trial to Study the Eff — Topline data from this positive-controlled Phase 3 trial of OmnImmune®.
Risks & what to watch (4)›
Key risks
- Going Concern and Cash Runway — Cash of £1.2M as of Dec 2024 only funds operations to June 2025; no committed financing in place [sec]
- Dependence on Single Lead Candidate — OmnImmune® is the sole lead product candidate; failure would severely impact the company [sec]
- Clinical Trial and Regulatory Risk — Uncertainty in trial outcomes and FDA approval; lengthy process may delay or deny approval [sec]
- No Revenue and Accumulated Losses — No product revenue; accumulated deficit of £51.0M; net loss of £12.2M in 2024 [sec]
What to watch
- Phase 3 topline data for OmnImmune® expected in 2027 and 2028 [catalyst]
- Financing events to extend runway beyond June 2025 [sec]
- Progress in CAR-T preclinical programs [sec]
Sources: SEC filings · Generated July 13, 2026 · How we verify sources →
Run TC BioPharm (Holdings) plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TC BioPharm (Holdings) plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 1.40
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~304d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for TC BioPharm (Holdings) plc?
TC BioPharm is a clinical-stage biotechnology company developing GD-T cell therapies, with lead candidate OmnImmune® in Phase 3 trials for oncology indications.
What is TC BioPharm (Holdings) plc's next catalyst?
TC BioPharm (Holdings) plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the" — expected June 30, 2027.
Who is the CEO of TC BioPharm (Holdings) plc?
Mr. Bryan Leland Kobel is the chief executive officer of TC BioPharm (Holdings) plc (TCBWF).
Where is TC BioPharm (Holdings) plc headquartered?
TC BioPharm (Holdings) plc (TCBWF) is headquartered in Motherwell, United Kingdom.
What therapeutic areas does TC BioPharm (Holdings) plc focus on?
TC BioPharm (Holdings) plc develops therapies across Oncology, Infectious Disease, Respiratory, Hematology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.